yousef kayed

Dr. yousef kayed

Faculty of Pharmacy, Misr International University, Cairo, Al Qāhirah, Egypt
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2025 in Microbes & Immunity
Verified
Journal Article
Open access
PDF file
yousef kayedyousef kayed
yousef kayed
SASahar AbdelRaouf
Sahar AbdelRaouf
WEWafaa Nabil Eltayeb
Wafaa Nabil Eltayeb
Human immunodeficiency virus (HIV) is a pathogenic virus capable of entering the human body and replicating within T cells, ultimately leading to acquired immunodeficiency syndrome. In contrast, GB-virus C (GBV-C), a member of the Flaviviridae family, also infects humans but, according to current studies, is not associated with any known pathogenic effects. Unlike most RNA viruses, GBV-C encodes a single polyprotein. It is primarily transmitted through blood and sexual contact. GBV-C comprises three strains: GBV-C, hepatitis G virus (HGV), and other less-studied strains. The HGV strain has been detected in patients with liver cirrhosis; however, there is no evidence that it causes liver disease. Notably, GBV-C reduces immune activation in HIV-infected patients. It has been shown to have a significant effect on the target cell receptors for HIV, indicating its potential as a model for vaccine development against HIV. However, there is a lack of information and studies concerning this virus. GBV-C-based vaccine development faces many challenges, such as concerns about safety and efficacy, limited understanding of its mechanisms of action and immunogenicity, HIV strain variability, ethical and regulatory considerations, production and delivery logistics, long-term outcomes, and public perception and acceptance. Nevertheless, bioinformatic techniques can play a crucial role in overcoming these challenges through approaches such as comparative genomics, epitope mapping, structural bioinformatics, and vaccine design and optimization.

6 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
yousef kayedyousef kayed
yousef kayed
SASahar AbdElRaouf
Sahar AbdElRaouf
WEWafaa Nabil Eltayeb
Wafaa Nabil Eltayeb
Human immunodeficiency virus (HIV ) is one of the pathogenic viruses that enter the human body and replicate in T-cells, leading to acquired immunodeficiency syndrome ( AIDS). On the other hand, GB-virus C (GBV-C) is a virus that enters the human body without known pathogenic effects on the human body. It is mostly related to the Flaviviridae family, especially hepatitis C (HCV).To our knowledge, studies show that this virus is not associated with any disease. The viral composition differs from most known RNA viruses as it encodes a single polyprotein. The virus could be transmitted through blood and sexual contact. The GBV-C includes three different strains: GBV-C, Hepatitis G virus (HGV), and non-studied one. HGV strain has been detected in patients with liver cirrhosis. However, there is no evidence that it causes liver disease. GBV-C reduces immunity activation in HIV-infected patients. It has been found that it has a marked effect on the target cell receptors for HIV indicating that it could be studied to design a vaccine against HIV. However, there is a lack of information and studies concerning the virus. Many challenges are faced when developing a vaccine based on a virus. These challenges include safety and efficacy, mechanism of action for GBV-C, immunogenicity, variability in HIV Strains, ethical and regulatory issues, production and delivery, long-term outcomes, and public perception and acceptance. However, bioinformatics techniques can play a crucial role in overcoming these challenges by several methods that are: comparative genomics, epitope mapping, structural bioinformatics, and vaccine design and optimization.